Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05455866 | Central Venous Catheter-related Complications in Patients Under Anticancer Treatment(KTcCHO) | unknown | — | 100 | Centre Hospitalier Alpes LemanOTHER | 0 | Jul 13, 2022 | clinicaltrials |
| NCT05378178 | A PhaseⅠStudy of HS-10381 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 51 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 7, 2022 |
| clinicaltrials |
| NCT03758664 | Clinical Study of ICP-192 in Solid Tumors Patients | unknown | Phase 1 / Phase 2 | 56 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05441046 | Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 | 120 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05442996 | A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 30 | Shanghai Henlius BiotechINDUSTRY | 0 | Jul 5, 2022 | clinicaltrials |
| NCT05349409 | A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers | unknown | Phase 2 | 212 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 30, 2022 | clinicaltrials |
| NCT04750772 | Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal Cancer | unknown | N/A | 60 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 27, 2022 | clinicaltrials |
| NCT05019794 | Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations(FGFR) | unknown | Phase 2 | 80 | LianBio LLCINDUSTRY | 1 | Jun 27, 2022 | clinicaltrials |
| NCT05429398 | A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor | unknown | Phase 1 | 118 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Jun 23, 2022 | clinicaltrials |
| NCT05369312 | Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients | unknown | Phase 1 | 230 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT05216965 | A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors | unknown | Phase 1 / Phase 2 | 208 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Jun 15, 2022 | clinicaltrials |
| NCT04058587 | A Phase I Trial of Simmitinib in Advanced Solid Tumors | unknown | Phase 1 | 50 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jun 6, 2022 | clinicaltrials |
| NCT05393063 | A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 36 | AkesoINDUSTRY | 0 | May 26, 2022 | clinicaltrials |
| NCT05385081 | PREcision Medicine in Cancer in Odense, Denmark(PRECODE) | unknown | N/A | 900 | Odense University HospitalOTHER | 1 | May 23, 2022 | clinicaltrials |
| NCT05228600 | YL-13027 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 54 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | May 20, 2022 | clinicaltrials |
| NCT05380986 | Camrelizumab Combined With Apatinib Mesylate | unknown | N/A | 500 | Henan Cancer HospitalOTHER_GOV | 1 | May 19, 2022 | clinicaltrials |
| NCT05382377 | NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors | unknown | Early Phase 1 | 18 | jianming xuOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT05369286 | A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors | unknown | Phase 1 | 28 | Maxinovel Pty., Ltd.INDUSTRY | 1 | May 11, 2022 | clinicaltrials |
| NCT05370755 | A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors | unknown | Phase 1 | 22 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | May 11, 2022 | clinicaltrials |
| NCT04963972 | Digital and Behavioral Tele-Health Tapering Program for Lowering Dependence on Opioids in Patients Undergoing Surgery | unknown | N/A | 272 | Lucid Lane, IncINDUSTRY | 1 | May 10, 2022 | clinicaltrials |
| NCT05228119 | A Study of Oncolytic Virus Injection (RT-01) in Combination With PD-1 Inhibitor in Patients With Advanced Solid Tumors | unknown | Phase 1 | 50 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT04579978 | Tumor Immunotherapy and Microbiome Analysis(TIME) | unknown | — | 60 | Sunnybrook Health Sciences CentreOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT05360368 | HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 24 | Shanghai Henlius BiotechINDUSTRY | 1 | May 5, 2022 | clinicaltrials |
| NCT05354843 | SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors | unknown | Phase 1 | 37 | Etern BioPharma (Shanghai) Co., LtdINDUSTRY | 1 | Apr 29, 2022 | clinicaltrials |
| NCT04407897 | SOFT- Stereotactic Ablative Radiotherapy of Infra-diaphragmatic Soft Tissue Metastases(SOFT) | unknown | N/A | 121 | Herlev HospitalOTHER | 1 | Apr 28, 2022 | clinicaltrials |
| NCT05344742 | A Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid Tumors | unknown | Phase 1 | 116 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Apr 25, 2022 | clinicaltrials |
| NCT05341570 | A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668 | unknown | Phase 1 | 60 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 22, 2022 | clinicaltrials |
| NCT03646071 | A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 80 | NeuPharma, Inc.INDUSTRY | 1 | Apr 13, 2022 | clinicaltrials |
| NCT04082910 | Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Apr 13, 2022 | clinicaltrials |
| NCT05322720 | HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy | unknown | Phase 2 | 50 | Taizhou EOC Pharma Co., Ltd.INDUSTRY | 0 | Apr 12, 2022 | clinicaltrials |
| NCT04743388 | Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune System | unknown | — | 600 | National and Kapodistrian University of AthensOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05320640 | Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05322187 | Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy(sPLENTY-pc) | unknown | Phase 2 / Phase 3 | 15 | RenJi HospitalOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05218148 | SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma | unknown | Phase 2 | 44 | Aiping ZhouUNKNOWN | 1 | Apr 6, 2022 | clinicaltrials |
| NCT04602702 | Hyper-Personalized Medicine Using Patient Derived Xenografts (PDXovo) for Metastatic Solid Tumors(PDXovo) | unknown | — | 50 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT02637531 | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | unknown | Phase 1 | 219 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 4, 2022 | clinicaltrials |
| NCT03835949 | Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer | unknown | Phase 1 | 36 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Apr 1, 2022 | clinicaltrials |
| NCT04381221 | Observational MyPal-Child Study on the ePRO-based Early Palliative Care Digital System in Paediatric Oncology Patients(MyPal4Kids) | unknown | — | 100 | Centre for Research and Technology HellasOTHER | 2 | Mar 29, 2022 | clinicaltrials |
| NCT05202561 | A Study of RNA Tumor Vaccine in Patients With Advanced Solid Tumors | unknown | Phase 1 | 10 | The First Affiliated Hospital of Bengbu Medical UniversityOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT05287165 | Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms | unknown | Early Phase 1 | 19 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Mar 18, 2022 | clinicaltrials |
| NCT05284968 | RD07 Cell Injection in the Treatment of Patients With Advanced Claudin18.2 Positive Solid Tumors | unknown | Early Phase 1 | 36 | Peking UniversityOTHER | 0 | Mar 17, 2022 | clinicaltrials |
| NCT05282784 | Hyperthermia With Flexible Electrode-typed 2-MHz Device During Radiotherapy for Solid Tumors | unknown | N/A | 20 | Yonsei Hyperthermia Study GroupOTHER | 0 | Mar 16, 2022 | clinicaltrials |
| NCT05258266 | A Study to Evaluate the Activity, Safety and Tolerability of ZX-101A in Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 76 | Nanjing Zenshine PharmaceuticalsINDUSTRY | 1 | Mar 14, 2022 | clinicaltrials |
| NCT05277454 | Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT | unknown | Phase 1 | 113 | Hutchison Medipharma LimitedINDUSTRY | 1 | Mar 14, 2022 | clinicaltrials |
| NCT05278832 | A Study of QLS31905 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 104 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 14, 2022 | clinicaltrials |
| NCT05275062 | Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma | unknown | Early Phase 1 | 6 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Mar 11, 2022 | clinicaltrials |
| NCT05274191 | An Exploratory Basket Study of Pyrotinib Maleate Tablets in HER2 Mutated or Amplified of Metastatic Solid Tumors | unknown | Phase 2 | 60 | Zhongshan Hospital Xiamen UniversityOTHER | 0 | Mar 10, 2022 | clinicaltrials |
| NCT04407676 | Improving Informed Consent for Early Phase Anti-Cancer Trials(CONSENT) | unknown | N/A | 34 | Royal Marsden NHS Foundation TrustOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT05254665 | A Study of Docetaxel Polymeric Micelles for Injection in Patients With Advanced Solid Tumors | unknown | Phase 2 | 110 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 24, 2022 | clinicaltrials |
| NCT05252975 | Improving Cyberknife Spinal Stereotactic Radiotherapy in Difficult to Treat Cases (IMPRESS)(IMPRESS) | unknown | N/A | 10 | Royal Marsden NHS Foundation TrustOTHER | 1 | Feb 23, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Jul 13, 2022source: clinicaltrials